MaxCyte EBIT

MaxCyte (MXCT) currently reports a EBIT of $-38M as of March 2026. That compares with $-49M in the prior-year period — up 23.4% year over year. That is below the Materials sector average of $15B. Use the charts on this page to explore MaxCyte's EBIT history and peer comparisons.

MaxCyte's EBIT increased from $-49M to $-38M — a 23.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MaxCyte's EBIT of $-38M is lower than the Materials sector average of $15B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

MaxCyte reported $-38M in EBIT as of March 2026. That compares with $-49M in the prior-year period — up 23.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-38M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Materials average is $15B. From there, open related valuation or income-statement pages for MaxCyte, and consider following MXCT for alerts when major investors trade the stock.